Competitive CBFβ/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): A pilot study

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1519-1525

  Laczika, Klaus ^a   Novak, Michael ^a   Hilgarth, Bernadette ^a   Mitterbauer, Margit ^a   Mitterbauer, Gerlinde ^a   Scheidel Petrovic, Alexander ^a   Scholten, Christine ^a   Thalhammer Scherrer, Renate ^a   Brugger, Stefan ^a   Keil, Felix ^a   Schwarzinger, Ilse ^a   Haas, Oskar A ^a   Lechner, Klaus ^a   Jaeger, Ulrich ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; ANTINEOPLASTIC AGENT; CBFBETA MYH11 FUSION PROTEIN; CBFBETA-MYH11 FUSION PROTEIN; MESSENGER RNA; ONCOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHROMOSOME INVERSION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MINIMAL RESIDUAL DISEASE; MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADOLESCENT; BONE MARROW; COMPARATIVE STUDY; GENETICS; KINETICS; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PILOT STUDY; POLYMERASE CHAIN REACTION; REMISSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW TRANSPLANTATION; HUMANS; INVERSION, CHROMOSOME; KINETICS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PILOT PROJECTS; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; RNA, MESSENGER;

EID: 0031596536     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1519     Document Type: Article

References (45)

1. Rowley JD: Recurring chromosomal abnormalities in leukemia and lymphoma. Semin Hematol 27:122-136, 1990
2. Bitter MA, LeBeau MM, Rowley JD, et al: Association between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol 18:211-215, 1987
3. Berger R, Flandrin G, Bernheim A, et al: Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias. Cancer Genet Cytogenet 29:9-21, 1987
4. Tashiro S, Kyo T, Tanaka K, et al: The prognostic value of cytogenetic analyses in patients with acute nonlymphocytic leukemia treated with the same intensive chemotherapy. Cancer 70:2809-2815, 1992
5. Haferlach T, Gassmann W, Löffler H, et al: Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. Ann Hematol 66:165-170, 1993
6. Marosi C, Köller U, Koller-Weber E, et al: Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 61:14-25, 1992
7. Bloomfield CD, Lawrence D, Arthur DC, et al: Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84:111a, 1994 (suppl 1, abstr 431)
8. Bloomfield CD, Baer MR, Herzig GP: Acute myeloid leukemia in adults: An update. Education Programme of the Second Meeting of the European Haematology Association, Paris, France, 1996, p 91
9. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
10. Ghaddar HM, Plunkett W, Kantarjian HM, et al: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8:1269-1274, 1994
11. Löwenberg B: Post remission treatment of acute myelogenous leukemia. N Engl J Med 332:260-262, 1995 (editorial)
12. Bartram CR: Detection of minimal residual leukemia by the polymerase chain reaction: Potential implications for therapy. Clin Chim Acta 217:75-83, 1993
13. Mayer RJ: Allogeneic transplantation versus intensive chemotherapy in first remission acute leukemia: Is there a "best choice"? J Clin Oncol 6:1532-1536, 1988 (editorial)
14. Liu PP, Hajra A, Wijmenga C, et al: Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 85:2289-2302, 1995
15. Liu P, Tarlé SA, Hajra A, et al: Fusion between transcription factor CBFβ/PEBP2β and myosin heavy chain in acute myeloid leukemia. Science 261:1041-1044, 1993
16. Claxton DF, Liu P, Hsu HP, et al: Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 83:1750-1756, 1994
17. van der Reijden BA, Lombardo M, Dauwerse HG, et al: RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFβ-MYH11 transcripts. Blood 86:277-282, 1995
18. Poirel H, Radford-Weiss I, Rack K, et al: Detection of chromosome 16 CBFβ-MYH11 fusion transcript in myelomonocytic leukemias. Blood 85:1313-1322, 1995
19. Tobal K, Johnson PRE, Saunders MJ, et al: Detection of CBFβ/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol 91:104-108, 1995
20. Shurtleff SA, Meyers S, Hiebert SW, et al: Heterogeneity in CBFβ/MYH11 fusion messages encoded by the inv(16)(p13;q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood 85:3695-3703, 1995
21. Hébert J, Cayuela JM, Daniel MT, et al: Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood 84:2291-2296, 1994
22. Campana D, Pui C-H: Detection of minimal residual disease in acute leukemia: Methodological advances and clinical significance. Blood 85:1416-1434, 1995
23. Costello R, Sainty D, Biaise D, et al: Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBFβ/MYH11-positive acute myeloblastic leukemia. Blood 89:2222-2223, 1997 (letter)
24. Cross NCP, Feng L, Chase A, et al: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929-1936, 1993
25. Muto A, Mon S, Matsushita H, et al: Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukemia with competitive PCR-assay. Br J Haematol 95:85-94, 1996
26. Thalhammer F, Geissler K, Jäger U, et al: Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single center study. Ann Hematol 72:216-222, 1996
27. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
28. Kusec R, Laczika K, Knöbl P, et al: AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8:735-739, 1994
29. Matsuoka R, Yoshida MC, Furutani Y, et al: Human smooth muscle myosin heavy chain gene mapped to chromosomal region 16q12. Am J Med Genet 46:61-67, 1993
30. Kwok S, Higuchi R: Avoiding false positives with the PCR. Nature 339:237-238, 1989
31. Ng S-Y, Gunning P, Eddy R, et al: Evolution of the functional human β-actin gene and its multi-pseudogene family: Conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol 5:2720-2732, 1985
32. Novak M, Laczika K, Mitterbauer M, et al: Novel CBFβ-MYH11 fusion transcripts and alternative splicing in acute myeloid leukemia with inversion of chromosome 16. Blood 86:2449-2450, 1995 (letter)
33. Lion T, Henn T, Gaiger A, et al: Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukemia. Lancet 341:275-276, 1993
34. Gaiger A, Henn T, Hörth E, et al: Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia preceding disease progression. Blood 86:2371-2178, 1995
35. Haas OA, Schwarzmeier JD, Nacheva E, et al: Investigations on karyotype evolution in patients with chronic myeloid leukemia (CML). Blut 48:33-43, 1984
36. Mitelman F, Rowley JD, Sakurai M: Long term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on chromosomes in leukemia. Cancer Genet Cytogenet 73:1-7, 1994
37. van Rhee F, Marks DI, Lin F, et al: Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: Comparison of blood and bone marrow. Leukemia 9:329-335, 1995
38. Nucifora G, Rowley JD: AML1 and the 8;21 and 3;21 translocations in acute and chronic leukemia. Blood 86:1-14, 1995
39. Jurlander J, Caligiuri MA, Ruutu T, et al: Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 88:2183-2191, 1996
40. Laczika K, Mitterbauer G, Korninger L, et al: Rapid achievement of PML/RARα polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: A pilot study. Leukemia 8:1-5, 1994
41. Evans PAS, Short MA, Jack AS, et al: Detection and quantification of the CBFβ/MYH11 transcripts associated with the inv(16) in the presentation and follow-up samples from patients with AML. Leukemia 11:364-369, 1997
42. Brisco MJ, Condon J, Hughes E, et al: Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet 343:196-200, 1994
43. Scholten C, Födinger M, Mitterbauer M, et al: Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia. Ann Hematol 71:155-160, 1995
44. Heid CA, Stevens J, Livak KJ, et al: Real time quantitative PCR. Genome Res 6:986-994, 1996
45. Marcucci G, Livak KJ, Bi WL, et al: Detection of AML1/ETO transcript in patients with t(8;21)-associated AML using a novel "real time" quantitative RT-PCR assay. Blood 90:390a, 1997 (suppl 1, abstr 1735)